Research Studies
Back to Results
A Phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
Description
This is a phase II, randomized, double-blind, trial for the use of Rucaparib as maintenance therapy in metastatic and recurrent endometrial cancer.
Details
Age
Adult
Eligibility
Females aged 18-89 with primary stage III/IV or recurrent endometrial cancer whom have received at least one prior chemotherapy regimen and no more than two prior cytoxic regimens (including hormonal therapy).
Phase
II - Research Studies that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug's effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.
Type of Study
Treatment
Locations
Fox Chase Cancer Center
University of Colorado Hospital
University of Pennsylvania
Principal Investigator
Bradley Corr, MD
Study ID
Protocol Number: 18-0567
More information available at ClinicalTrials.gov: NCT03617679
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers